Bumetanide Inj Rx
Generic Name and Formulations:
Bumetanide 0.25mg/mL; contains benzyl alcohol.
Various generic manufacturers
Indications for Bumetanide Inj:
Initially 0.5–1mg IM or IV. May give 1–2 more doses at 2–3 hour intervals; max 10mg/day.
<18yrs: not recommended.
Anuria. Infants. Hepatic coma. Severe electrolyte depletion.
Hepatic cirrhosis. Ascites. Progressive renal disease. Gout. Diabetes. Postsympathectomy. Monitor electrolytes, blood, liver function. May need K+ supplementation. K+ losing nephropathy. Discontinue if renal dysfunction progresses. Aldosterone excess. Ventricular arrhythmias. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
May increase digitalis, lithium toxicity. Hypokalemia with digitalis, diuretics in CHF. Alcohol, CNS depressants increase orthostatic hypotension. Avoid probenecid, indomethacin. Ototoxicity may be potentiated with aminoglycosides.
Muscle cramps, dizziness, hypotension, headache, nausea, encephalopathy, ototoxicity, rash, fluid or electrolyte imbalance, hyperglycemia, hyperuricemia, blood dyscrasias.
Formerly known under the brand name Bumex.
Sign Up for Free e-newsletters
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- Age Not a Deterrent to Immunotherapy for Malignant Melanoma
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Bedside Assessment Tool Improves Worst Pain in Patients With Cancer
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|